Literature DB >> 17428516

Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques.

Deborah Heydenburg Fuller1, Tim Shipley, Todd M Allen, James T Fuller, Mary S Wu, Helen Horton, Nancy Wilson, Georg Widera, David I Watkins.   

Abstract

An effective HIV vaccine will likely need to induce broad and potent CTL responses. Epitope-based vaccines offer significant potential for inducing multi-specific CTL, but often require conjugation to T helper epitopes or carrier moieties to induce significant responses. We tested hybrid DNA vaccines encoding one or more HIV or SIV CTL epitopes fused to a hepatitis B core antigen (HBcAg) carrier gene as a means to improve the immunogenicity of epitope-based DNA vaccines. Immunization of mice with a HBcAg-HIV epitope DNA vaccine induced CD8(+) T cell responses that significantly exceeded levels induced with DNA encoding either the whole HIV antigen or the epitope alone. In rhesus macaques, a multi-epitope hybrid HBcAg-SIV DNA vaccine induced CTL responses to 13 different epitopes, including 3 epitopes that were previously not detected in SIV-infected macaques. These data demonstrate that immunization with hybrid HBcAg-epitope DNA vaccines is an effective strategy to increase the magnitude and breadth of HIV-specific CTL responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17428516      PMCID: PMC6286304          DOI: 10.1016/j.virol.2007.02.024

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  63 in total

Review 1.  Cellular immune responses to HIV.

Authors:  A J McMichael; S L Rowland-Jones
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

2.  Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.

Authors:  T M Allen; T U Vogel; D H Fuller; B R Mothé; S Steffen; J E Boyson; T Shipley; J Fuller; T Hanke; A Sette; J D Altman; B Moss; A J McMichael; D I Watkins
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

3.  DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Authors:  Margherita Rosati; Agneta von Gegerfelt; Patricia Roth; Candido Alicea; Antonio Valentin; Marjorie Robert-Guroff; David Venzon; David C Montefiori; Phil Markham; Barbara K Felber; George N Pavlakis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles.

Authors:  M L Michel; M Mancini; E Sobczak; V Favier; D Guetard; E M Bahraoui; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

5.  A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS.

Authors:  Dinesh K Singh; Zhenqian Liu; Darlene Sheffer; Glenn A Mackay; Marilyn Smith; Sukhbir Dhillon; Ramakrishna Hegde; Fenglan Jia; Istvan Adany; Opendra Narayan
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen.

Authors:  S Le Borgne; M Mancini; R Le Grand; M Schleef; D Dormont; P Tiollais; Y Rivière; M L Michel
Journal:  Virology       Date:  1998-01-20       Impact factor: 3.616

7.  A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing.

Authors:  L A Knapp; E Lehmann; M S Piekarczyk; J A Urvater; D I Watkins
Journal:  Tissue Antigens       Date:  1997-12

8.  Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.

Authors:  A Vitiello; G Ishioka; H M Grey; R Rose; P Farness; R LaFond; L Yuan; F V Chisari; J Furze; R Bartholomeuz
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

9.  Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.

Authors:  S J Kent; A Zhao; S J Best; J D Chandler; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.

Authors:  M Kovacsovics-Bankowski; K Clark; B Benacerraf; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

View more
  8 in total

1.  DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.

Authors:  Lara Vojnov; Alexander T Bean; Eric J Peterson; Maria J Chiuchiolo; Jonah B Sacha; Ferencz S Denes; Matyas Sandor; Deborah H Fuller; James T Fuller; Christopher L Parks; Adrian B McDermott; Nancy A Wilson; David I Watkins
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

2.  Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants.

Authors:  Rui Gu; Cristy Stagnar; Lesya Zaichenko; Arlene I Ramsingh
Journal:  Vaccine       Date:  2012-03-29       Impact factor: 3.641

3.  A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules.

Authors:  Susan Pereira Ribeiro; Daniela Santoro Rosa; Simone Gonçalves Fonseca; Eliane Conti Mairena; Edilberto Postól; Sergio Costa Oliveira; Luiza Guilherme; Jorge Kalil; Edecio Cunha-Neto
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

4.  Broad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides.

Authors:  Rafael Ribeiro Almeida; Daniela Santoro Rosa; Susan Pereira Ribeiro; Vinicius Canato Santana; Esper Georges Kallás; John Sidney; Alessandro Sette; Jorge Kalil; Edecio Cunha-Neto
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

5.  Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques.

Authors:  Deborah Heydenburg Fuller; Premeela Rajakumar; Jenny W Che; Amithi Narendran; Julia Nyaundi; Heather Michael; Eric J Yager; Cristy Stagnar; Brendon Wahlberg; Rachel Taber; Joel R Haynes; Fiona C Cook; Peter Ertl; John Tite; Angela M Amedee; Michael Murphey-Corb
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

6.  In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.

Authors:  Negar Seyed; Farnaz Zahedifard; Shima Safaiyan; Elham Gholami; Fatemeh Doustdari; Kayhan Azadmanesh; Maryam Mirzaei; Nasir Saeedi Eslami; Akbar Khadem Sadegh; Ali Eslami Far; Iraj Sharifi; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2011-09-06

7.  Structural integrity of the antigen is a determinant for the induction of T-helper type-1 immunity in mice by gene gun vaccines against E. coli beta-galactosidase.

Authors:  Tekalign Deressa; Angelika Stoecklinger; Michael Wallner; Martin Himly; Stefan Kofler; Katrina Hainz; Hans Brandstetter; Josef Thalhamer; Peter Hammerl
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

8.  Multigenic DNA vaccine induces protective cross-reactive T cell responses against heterologous influenza virus in nonhuman primates.

Authors:  Merika T Koday; Jolie A Leonard; Paul Munson; Adriana Forero; Michael Koday; Debra L Bratt; James T Fuller; Robert Murnane; Shulin Qin; Todd A Reinhart; Karen Duus; Ilhem Messaoudi; Amy L Hartman; Kelly Stefano-Cole; Juliet Morrison; Michael G Katze; Deborah Heydenburg Fuller
Journal:  PLoS One       Date:  2017-12-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.